Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway  by Akimoto, Tetsu et al.
Kidney International, Vol. 58 (2000), pp. 269–282
Erythropoietin regulates vascular smooth muscle cell apoptosis
by a phosphatidylinositol 3 kinase-dependent pathway
TETSU AKIMOTO, EIJI KUSANO, TOSHIYA INABA, OSAMU IIMURA, HIDEAKI TAKAHASHI,
HIROMI IKEDA, CHIHARU ITO, YASUHIRO ANDO, KEIYA OZAWA, and YASUSHI ASANO
Departments of Nephrology and Molecular Biology, Jichi Medical School, Tochigi, Japan
Erythropoietin regulates vascular smooth muscle cell apoptosis dilation, neurotransmission, platelet aggregation, im-
by a phosphatidylinositol 3 kinase-dependent pathway. mune responses to microorganisms, and tumor cells
Background. Recent studies have shown that several cyto- [1–3]. It is released by the cells that contain the constitu-kines could induce apoptosis in vascular smooth muscle cells
tive type of NO synthase (cNOS) such as brain and(VSMCs) via the induction of nitric oxide (NO). In the present
endothelial cells [4–6]. On the other hand, there arestudy, we explored whether human recombinant erythropoietin
(rHuEPO) has a modulatory effect of apoptosis on interleukin- several reports that inflammatory cytokines, such as in-
1b (IL-1b) or NO donor sodium nitroprusside (SNP)-induced terleukin-1b (IL-1b), tumor necrosis factor-a (TNF-a),
apoptosis in rat cultured VSMCs.
and interferon-g (IFN-g) can strongly stimulate largeMethods. The quantitation of apoptosis among VSMCs was
amounts of NO production via inducible NO synthaseassessed by nuclear morphological analysis with fluorescent
DNA-binding dye Hoechst 33258. Apoptotic changes were also (iNOS) in several types of tissue, including vascular
confirmed by the detection of DNA fragmentation. The expres- smooth muscle cells (VSMCs) [1, 7–11]. In addition, re-
sion of EPO receptor (EpoR), cellular protein tyrosine phos- cent studies have shown that these cytokines could in-phorylation, including EpoR and Janus kinase (JAK) 2, and
duce apoptosis in VSMCs via induction of NO [12, 13].the association of p85 subunit of phosphatidylinositol 3 kin-
Also, it is reported that NO per se induces apoptosis inase (PI3-kinase) to tyrosine-phosphorylated proteins, including
EpoR, were explored by using Western blotting analysis com- VSMCs [14–16].
bined in part with immunoprecipitation. Erythropoietin (EPO) is a serum glycoprotein that is
Results. rHuEPO inhibited the apoptosis induced by IL-1b synthesized mainly in the kidneys and regulates survival,or SNP in a dose- and time-dependent manner. The anti-apo-
proliferation, and differentiation by preventing an apo-ptotic effects of rHuEPO were diminished in the presence
ptosis of erythroid precursor cells via its own receptorof a tyrosine kinase (TK) inhibitor genistein or anti-EpoR
antibody. After stimulation with rHuEPO, EpoR and JAK 2 [17, 18]. EPO receptor (EpoR), a family of cytokine
were tyrosine phosphorylated, and p85 subunits were associated receptors, lacks tyrosine kinase (TK) consensus se-
with EpoR. Also, rHuEPO induced phosphorylation of Akt
quences in the intracellular domain. However, it hasthrough a PI3-kinase–dependent pathway. The phosphoryla-
been shown that EPO immediately induces the tyrosinetion of Akt and the anti-apoptotic effects of rHuEPO were
diminished in the presence of a PI3-kinase inhibitor, wort- phosphorylation of its own receptor, as well as a number
mannin. of cellular proteins [19–21]. The first step of this intracel-
Conclusion. Our present study demonstrates that rHuEPO lular signaling is EPO-induced homodimerization of the
inhibites IL-1b or SNP-induced VSMC apoptosis. The TK-
EpoR and places Janus kinase (JAK) 2 molecule, whichdependent pathway, particularly the PI3-kinase–dependent
is constitutively associated with the EpoR, in close prox-pathway, seems to be critical to the countervailing effect of
rHuEPO on IL-1b and SNP-induced VSMC apoptosis. imity, thus promoting trans-tyrosine phosphorylation
and activation of the TK JAK 2 [19]. Following tyrosine
phosphorylation of EpoR carried by an activated form
Nitric oxide (NO) is a multifunctional molecule, par- of JAK 2, as well as other cellular proteins, a number
ticipating in diverse physiological functions, such as vaso-
of Src homology 2 (SH2)-containing proteins, such as
phosphatidylinositol 3-kinase (PI3-kinase), become as-
sociated with them, and their biological functions areKey words: cell death, anemia, inflammatory cytokines, nitric oxide,
signaling, tyrosine kinase JAK 2. activated [19, 22, 23].
It has been reported that PI3-kinase suppresses apo-
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the activation of PI3-kinase/Akt signal transduction Cell culture
pathway, which may be necessary to promote viability Vascular smooth muscle cells were prepared from the
of the hematopoietic cell line [27]. rat aortas of male Sprague-Dawley rats (150 to 200 g)
There are several reports suggesting that EpoR as previously described [9]. In brief, cells were grown in
mRNA is expressed in vascular endothelial cells and Dulbecco’s modified Eagle’s medium (DMEM) supple-
smooth muscle cells [28–30]. This collective evidence mented with 10% fetal bovine serum (ICN Biomedicals,
supports the hypothesis of its biological effect on the Osaka, Japan), 100 U/mL penicillin, and 100 mg/mL
vessel wall. Indeed, it is reported that rHuEPO has both streptomycin (Life Technology Inc., Rockville, MD,
a direct vasoconstrictor effect on isolated renal and mes- USA) in a 5% CO2 incubator at 378C to a subconfluent
enteric resistant vessels [31] and a mitogenic effect in state in 10 mm dishes or 24-well plates (Falcon). After
reaching subconfluence and rinsed twice with phosphate-VSMCs [32]. However, thus far, whether the EPO pos-
buffered saline (PBS), the cells were incubated with se-sesses a specific biological function through PI3-kinase/
rum-free DMEM for 24 hours, and then the experimentalAkt-dependent pathways in VSMCs remains to be eluci-
conditions were established. Cells grown to confluencedated.
were detached by a treatment with 0.125% trypsin andRecently, we observed that human recombinant EPO
0.02% ethylenediaminetetraacetic acid (EDTA) and re-(rHuEPO) significantly inhibits IL-1b–stimulated NO
seeded in secondary cultures and passages 3 through 7production via EpoR in cultured rat VSMCs [30, 33].
were used for experimentation.The aim of the present study was to explore whether
rHuEPO affects the apoptosis induced by IL-1b in
Determination of nitric oxideVSMCs. We found that rHuEPO significantly inhibited
Nitrite, a stable metabolite of NO, was measured asthe VSMC apoptosis induced by IL-1b in a dose- and
previously described [9, 30, 33]. Briefly, assay samplestime-dependent manner. The PI3-kinase–dependent path-
were mixed with an equal volume of the Griess reagentway appears to play a critical role in these antiapoptotic
(0.1% naphthylethylenediamine dihydrochloride andeffects of rHuEPO. Also, this study demonstrates that
1% sulfanilamide in 3% H3PO4) and incubated to yieldrHuEPO induced the phosphorylation of Akt through
a chromophore. Since phenol red interfered with nitritethe PI3-kinase–dependent pathway in VSMCs.
measurement to some degree, we used phenol red-free
DMEM for incubation. The absorbance at 570 nm was
METHODS measured, and the nitrite concentration was determined
using a curve calibrated from sodium nitrite standards.Materials
Protein content was measured by the Lowry method [34].
All materials were obtained from Sigma Chemical Co.
(St. Louis, MO, USA), except for those noted as follows: Morphological and quantitative analysis of apoptosis
IL-1b was purchased from Genzyme (Cambridge, MA, by fluorescence microscopy
USA). Anti-PI3-kinase antibody (p85) was purchased We used nuclear morphological analysis with fluores-
from Transduction Laboratory (Lexington, KY, USA). cent DNA-binding dyes Hoechst33258 (H33258) to as-
Anti-JAK 1 and JAK 2 antibodies were purchased from sess the rate of occurrence of apoptosis among VSMCs,
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Aga- basically as described by Pollman et al with some modi-
rose-conjugated antiphosphotyrosine [anti-Tyr(P)] mono- fications [15].
clonal antibody 4G10 was purchased from Upstate After completing the experimental condition, VSMCs
Biotechnology (Lake Placid, NY, USA). Horseradish were stained with H33258 (1 mg/mL, dissolved in DMEM)
peroxidase-conjugated anti-Tyr(P) monoclonal antibody for 10 minutes at 378C. Then floating cells and trypsin-
PY20, protein G sepharose, horseradish peroxidase-con- ized-attached cells were collected by centrifugation at
jugated antimouse, and antirabbit antibody were pur- 1000 r.p.m. for five minutes at 48C. Cell pellets were
chased from Amersham Pharmacia Biotech (Uppsala, resuspended in a small volume (100 mL) of PBS con-
Sweden). Anti-Akt and antiphosphorylated (Ser-473) taining 1 mg/mL H33258. An aliquot (20 mL) was placed
Akt antibodies were purchased from New England Bio- on the slide glass and covered with a glass cover slip.
Labs (Beverly, MA, USA). Antihuman EpoR mono- Then cells were observed under an Olympus fluorescent
clonal antibody was purchased from R&D Systems (Min- microscope. Individual nuclei were visualized at 3200 to
neapolis, MN, USA). Nuclear staining dye Hoechst detect the characteristic condensed coalesced chromatin
33258 was purchased from Molecular Probes (Eugene, pattern of apoptotic cells. The rate of occurrence of
OR, USA). rHuEPO (epoetin b) was a generous gift apoptosis as a percentage of the total cells present was
from the Chugai Pharmaceutical Company (Tokyo, calculated by more than 400 nuclei from random micro-
scopic fields. Scoring was performed by a single individ-Japan).
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ual, who had no information about the treatment, with Tween 20) with 5% bovine serum albumin. Then the
membranes were proved with indicated antibody (pri-an intra-assay variability of 5%. A second blinded indi-
vidual further verified the results of a representative set mary and secondary antibodies) followed by detection
using enhanced chemiluminescence (ECL) Western blot-of experiments with an interobserver variability of ,5%.
ting detection system (Amersham, Little Chalfont, UK)
Electrophoretic analysis of DNA fragmentation according to the manufacturer’s instructions.
To assess DNA fragmentation, fragmented DNA was
Statisticsobtained as previously described [35]. Briefly, to prepare
samples for gel electrophoresis, the VSMCs, which were The results are expressed as mean 6 SEM. Data
were analyzed by an analysis of variance combined withgrown to subconfluence on 100 mm dishes, were lyzed
by incubation in a 200 mL lysis buffer of 10 mmol/L Tris- Fisher’s protected least significant difference (Fisher’s
PLSD). Differences with P , 0.05 were considered toHCl, pH 7.5, 10 mmol/L EDTA, 0.5% Triton X-100
for 20 minutes at 48C. The lysates were centrifuged at be significant. Each figure represents one of at least three
separate experiments.22,000 3 g for 25 minutes, and the supernatant was
incubated with 0.4 mg/mL RNase for one hour at 378C
and 0.4 mg/mL proteinase K for one hour at 378C. The
RESULTS
fragmented DNA present in the supernatant was ex-
IL-1b induces apoptosis in VSMCstracted and precipitated in 50% isopropanol and 0.5
mol/L NaCl. The samples were resuspended in 20 mL of Previously, we reported that IL-1b stimulated NO pro-
duction in VSMCs in a dose- and time-dependent man-10 mmol/L Tris-HCl (pH 7.4), 0.5 mmol/L EDTA, and
separated by electrophoresis on 1% agarose gel con- ner [9]. Therefore, we first explored the effect of IL-1b
on VSMC apoptosis. As shown in Figure 1A, IL-1b in-taining ethidium bromide.
duced VSMC apoptosis in a dose-dependent manner.
Preparation of cell lysate and immunoprecipitation We also evaluated internucleosomal DNA fragmenta-
tion of genomic DNA extracted from VSMCs for furtherThe VSMCs, which were grown to confluence on 100
mm dishes, were rinsed with ice-cold PBS and resus- confirmation of apoptosis by using agarose gel electro-
phoresis. As shown in Figure 1B, internucleosomal DNApended into the 300 mL lysis buffer [1% Nonidet P-40,
20 mmol/L Tris-HCl, pH 7.5, 10% glycerol, 1 mmol/L fragmentation at 180 to 200 bp or multiples, which is
characteristic to apoptosis, appeared in IL-1b–treatedleupeptin, 1 mmol/L pepstatin A, 0.1 mmol/L phenyl-
methylsulfonyl fluoride (PMSF), 2 mmol/L sodium or- cells. Conversely, no detectable DNA fragmentation
was observed in the control. The addition of NO synthe-thovanadate]. After incubation for 30 minutes at 48C,
cell extracts were centrifuged at 22,000 3 g for 20 minutes sis inhibitor, l-NG-monomethyl arginine (L-NMMA; 3
mmol/L) or Nv-nitro-l-arginine methylester (L-NAME;to remove insoluble materials. Then the supernatants
were subjected to immunoprecipitation or total cell ly- 3 mmol/L) diminished the apoptotic cell or internucleo-
somal DNA fragmentation induced by 10 ng/mL IL-1bsate immunoblotting. For immunoprecipitation, 3 mg of
anti–PI3-kinase antibody (p85) were added to the super- (Fig. 1 A, B). Also, these agents completely inhibited
the NO synthesis induced by 10 ng/mL IL-1b (data notnatants and incubated overnight at 48C in an Eppendorf
shaker with protein G-Sepharose. Immunocomplexes shown).
Figure 1C shows nuclear morphological changes inwere collected by brief centrifugation and washed three
times with 1 mL of lysis buffer. The bound proteins were IL-1b–treated cells for 48 hours, with the most pro-
nounced changes observed at 10 ng/mL IL-1b. Fluores-eluted by heating at 958C for 10 minutes in 1 3 Laemmli’s
sodium dodecyl sulfate (SDS) sample buffer for Western cent staining of DNA with H33258 revealed a loss of
normal nuclear structure and the characteristic featuresblot analysis.
of apoptosis. These include patches of irregularly dis-
Western blotting analysis persed, pyknotic, and condensed chromatin.
The samples of the immunoprecipitates in Laemmli’s
NO induces apoptosis in VSMCssample buffer (discussed previously in this article) or
cell lysates in 5 3 Laemmli’s sample buffer, which were Next we explored whether NO per se induces apopto-
sis in VSMCs using NO donor sodium nitroprussideheated at 958C for 10 minutes, were separated by SDS-
10% polyacrylamide gel electrophoresis (SDS-PAGE) (SNP). As shown in Figure 2A, SNP induced VSMC
apoptosis in a dose-dependent manner. Also, internu-and electrophoretically transferred to nitrocellulose mem-
branes (Hybond-ECL; Amersham, Buckinghamshire, cleosomal DNA fragmentation at 180 to 200 bp or multi-
ples appeared in SNP-treated cells (Fig. 2B).UK). The membranes were incubated for blocking by a
60-minute treatment at room temperature in TBS-T Figure 2C shows nuclear morphological change in
SNP-treated cells for 24 hours, with the most pronounced(10 mmol/L Tris-HCl, pH 7.4, 100 mmol/L NaCl, 0.1%
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Fig. 1. Dose-dependent induction of vascular smooth muscle cell (VSMC) apoptosis by interleukin-1b (IL-1b). Cells were exposed to increasing
concentrations of IL-1b for 48 hours. (A) Analysis of the rate of occurrence of apoptosis in VSMCs. The percentage of apoptotic nuclei was
determined by the method described in the text. Data are means 6 SE of at least four separate experiments. *P , 0.05 vs. control; **P , 0.01
vs. control; ††P , 0.01 vs. addition of L-NMMA or P , 0.01 vs. addition of L-NAME. (B) Analysis of the DNA fragmentation. Nucleic acid
from sample was subjected to agarose gel electrophoresis. Lane 1, 100 base pair ladder; lane 2, control; lane 3, IL-1b (5 ng/mL); lane 4, IL-1b
(7.5 ng/mL); lane 5, IL-1b (10 ng/mL); lane 6, IL-1b (10 ng/mL) 1 L-NMMA (3 mmol/L); lane 7, IL-1b (10 ng/mL) 1 L-NAME (3 mmol/L). (C)
Nuclear morphologic change in VSMCs (original magnification 3200). Cells were treated with IL-1b (10 ng/mL) for 48 hours. Then cells were
stained with H33258 as described in the text. The figure shown represents one of three independent experiments.
changes observed at 1000 mmol/L SNP. Fluorescent on VSMC apoptosis induced by NO donor, SNP. Simi-
larly, rHuEPO inhibited SNP-induced apoptosis in astaining of DNA with H33258 revealed characteristic
features of the apoptosis described earlier in this article. dose- and time-dependent manner (Fig. 4).
Cellular mechanisms of the countervailing effect ofEffect of rHuEPO on IL-1b or NO-induced apoptosis
rHuEPO on IL-1b or NO-induced apoptosisPreviously, we observed that the rHuEPO inhibited
IL-1b–stimulated NO production in VSMCs [30, 33]. There are several reports that protein phosphoryla-
tion, including TK and serine-threonine kinase such asTherefore, we further explored the effect of rHuEPO
on IL-1b–induced VSMC apoptosis. rHuEPO inhibited the protein kinase C (PKC)-dependent pathway, is in-
volved in EpoR-mediated signal transduction [19–21, 30,IL-1b–induced apoptosis in a dose- and time-dependent
manner (Fig. 3). We also analyzed the effect of rHuEPO 36–38]. Therefore, we next explored the effect of TK
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Fig. 2. Dose-dependent induction of VSMC apoptosis by SNP. Cells were exposed to increasing concentrations of SNP for 24 hours. (A) Analysis
of the rate of occurrence of apoptosis in VSMCs. The percentage of apoptotic nuclei was determined by the method in the text. Data are means 6
SE of at least four separate experiments. *P , 0.05 vs. control; **P , 0.01 vs. control. (B) Analysis of the DNA fragmentation. Nucleic acid from
sample was subjected to agarose gel electrophoresis. Lane 1, 100 base pair ladder; lane 2, control; lane 3, SNP (250 mmol/L); lane 4, SNP (500
mmol/L); lane 5, SNP (1000 mmol/L). (C) Nuclear morphological change in VSMCs (original magnification 3200). Cells were treated with SNP
(1000 mmol/L) for 24 hours. Then cells were stained with H33258 as described in the text. The figure shown represents one of three independent
experiments.
inhibitor genistein or PKC inhibitor calphostin C on the of the anti-EpoR antibody (30 mg/mL), anti-apoptotic
effects of rHuEPO were also diminished as well as incountervailing effects of rHuEPO on IL-1b– or SNP-
induced apoptosis. As shown in Figure 5A, the effect of the genistein treatment (Fig. 5). These findings suggest
that the TK, not the PKC-dependent pathway, may be in-rHuEPO on IL-1b–induced apoptosis was completely
diminished in the presence of genistein (10 mmol/L) and volved in the countervailing effects of rHuEPO on IL-1b–
or SNP-induced apoptosis.was partially diminished in the presence of calphostin C
(1 mmol/L). On the other hand, the effect of rHuEPO In addition, we explored the effects on VSMC apopto-
sis of these protein kinase inhibitors or anti-EpoR anti-on SNP-induced apoptosis was also completely dimin-
ished in the presence of genistein; however, calphostin body alone. These agents could not induce significant
VSMC apoptosis. Percentages of apoptotic cells after 48C had no effect on the action of rHuEPO (Fig. 5B).
We further analyzed the effect of anti-EpoR antibody hours of treatment were as follows: control, 2.3 6 0.4%
(N 5 8); genistein (10 mmol/L), 2.5 6 0.4% (N 5 8);on these anti-apoptotic effects of rHuEPO to confirm the
specificity of these effects to rHuEPO. In the presence calphostin C (1 mmol/L), 2.4 6 0.4% (N 5 8); and anti-
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Fig. 3. Dose- and time-dependent effect of rHuEPO on IL-1b (10 ng/mL)-induced VSMC apoptosis. (A) Dose-dependent effect of rHuEPO.
Cells were treated with increasing concentrations of rHuEPO in the presence of 10 ng/mL IL-1b for 48 hours. *P , 0.05 vs. condition 2; **P ,
0.01 vs. condition 2; ††P , 0.01 vs. condition 1. (B) Time-dependent effect of rHuEPO. Cells were exposed to 250 U/mL rHuEPO in the presence
of 10 ng/mL IL-1b, and the quantity of apoptotic nuclei was assessed at the indicated time. Symbols are: (j) of 10 ng/mL IL-1b; (m, dotted line) of
10 ng/mL IL-1b 1 250 U/mL EPO; (d, double dashed line) control. **P , 0.01 vs. IL-1b alone; ††P , 0.01 vs. control. Data are means 6 SE
of at least four separate experiments.
Fig. 4. Dose- and time-dependent effects of rHuEPO on SNP (1000 mmol/L)-induced VSMC apoptosis. (A) Dose-dependent effect of rHuEPO.
Cells were treated with increasing concentrations of rHuEPO in the presence of 1000 mmol/L SNP for 24 hours. **P , 0.01 vs. condition 2; ††P ,
0.01 vs. condition 1. (B) Time-dependent effect of rHuEPO. Cells were exposed to 250 U/mL rHuEPO in the presence of 1000 mmol/L SNP, and
the quantity of apoptotic nuclei was assessed at the indicated time. Symbols are: (j) 1000 mmol/L SNP; (r, dotted line) 1000 mmol/L SNP 1 250
U/mL EPO; (d, dashed line) control. *P , 0.05 vs. SNP alone; **P , 0.01 vs. SNP alone; ††P , 0.01 vs. control. Data are means 6 SE of at
least four separate experiments.
EpoR antibody (30 mg/mL), 2.2 6 0.6% (N 5 8). Also, induced tyrosine phosphorylation and activation of JAK
2 followed by the tyrosine phosphorylation of a numberno obvious induction of DNA fragmentation was ob-
served in these conditions (data not shown). of cellular proteins, including its own receptor in hemato-
poietic cell lines [19–21]. Therefore, as a further step,
Protein tyrosine phosphorylation stimulated by we explored whether rHuEPO induces protein tyrosine
rHuEPO in VSMCs phosphorylation in the VSMC used in the present study.
As shown in Figure 6A, rHuEPO (250 U/mL) inducedIt has been reported that the first step of EPO-medi-
ated signal transduction is EpoR homodimerization- the tyrosine phosphorylation of proteins of about 145,
Akimoto et al: EPO and smooth muscle cell apoptosis 275
Fig. 5. Effect of protein kinase C (PKC) inhibitor, tyrosine kinase (TK) inhibitor, and anti-EpoR antibody on the countervailing effect of rHuEPO
on IL-1b– or SNP-induced VSMC apoptosis. (A) I. Calphostin C, genistein, or anti-EpoR antibody were added to the medium with rHuEPO
(250 U/mL) for 48 hours in the presence of 10 ng/mL IL-1b. II. Analysis of the DNA fragmentation. Nuclear acid from sample was subjected to
agarose gel electrophoresis. Lane 1, 100 bp ladder; lane 2, control; lane 3, IL-1b (10 ng/mL); lane 4, IL-1b (10 ng/mL) 1 rHuEPO (250 U/mL);
lane 5, IL-1b (10 ng/mL) 1 rHuEPO (250 U/mL) 1 calphostin C (1 mmol/L); lane 6, IL-1b (10 ng/mL) 1 rHuEPO (250 U/mL) 1 genistein (10
mmol/L). (B) I. Calphostin C, genistein, or anti-EpoR antibody was added to the medium with rHuEPO (250 U/mL) for 24 hours in the presence
of 1000 mmol/L SNP. II. Analysis of the DNA fragmentation. Lane 1, 100 bp ladder; lane 2, control; lane 3, SNP (1000 mmol/L); lane 4, SNP (1000
mmol/L) 1 rHuEPO (250 U/mL); lane 5, SNP (1000 mmol/L) 1 rHuEPO (250 U/mL) 1 calphostin C (1 mmol/L); lane 6, SNP (1000 mmol/L) 1
rHuEPO (250 U/mL) 1 genistein (10 mmol/L). Data are means 6 SE of at least four separate experiments. *P , 0.05; **P , 0.01.
130, 70, 60, 40, and 30 kD molecular masses. The tyrosine phosphorylated 72 kD form of the EpoR in-
creased. Figure 6D shows that JAK 2 was constitutivelyrHuEPO-induced tyrosine phosphorylation of these pro-
teins was rapid, with the maximal effect being achieved expressed in the VSMCs, and the addition of rHuEPO
could induce tyrosine phosphorylation of JAK 2. JAK 1after a three- to five-minute exposure to rHuEPO. Dose-
was also constitutively expressed in the VSMC; however,dependent studies showed that the amount of tyrosine
no tyrosine phosphorylation induced by rHuEPO wasphosphorylated proteins continuously increased as the
observed (Fig. 6D).concentration of rHuEPO was increased, and a maximal
level was reached at 250 U/mL of rHuEPO (Fig. 6B).
Association of p85 with tyrosine-phosphorylatedIn addition, we explored whether EpoR and JAK 2
proteins after stimulation with rHuEPO in VSMCswere also tyrosine phosphorylated in VSMCs. Figure 6C
shows that the EpoR was constitutively expressed in Phosphatidylinositol 3 kinase is a heterodimer phos-
pholipid kinase composed of an 85 kD (p85) regulatorythe VSMCs, and after stimulation with rHuEPO, the
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subunit and a 110 kD (p110) catalytic subunit [39]. More- control, 2.7 6 0.4% (N 5 8), and wortmannin (0.1
over, PI3-kinase is activated by the association of p85 mmol/L), 1.9 6 0.4% (N 5 8).
regulatory subunit with tyrosine-phosphorylated pro-
teins, including EpoR through its SH2 domain [22, 23].
DISCUSSIONTherefore, we explored whether the p85 subunit was
The present study clearly demonstrates, to our knowl-associated with tyrosine-phosphorylated protein, includ-
edge for the first time, that rHuEPO inhibits IL-1b– oring EpoR, in VSMCs after stimulation with rHuEPO.
SNP-induced VSMC apoptosis through EpoR, and theAs shown in Figure 7 A and B, Western blot analysis
PI3-kinase–dependent pathway might be involved inwith anti-p85 revealed that rHuEPO rapidly induced the
association of p85 to EpoR or tyrosine-phosphorylated these anti-apoptotic effects of rHuEPO.
protein. Also, total cell lysates were immunoprecipitated Previous reports have shown that cytokines such as
with p85 antibody. Immunoblot with p85 antibody re- IL-1b, TNF-a, and IFN-g could induce apoptosis in
vealed that the p85 subunit was constitutively expressed VSMCs via the induction of NO [12, 13]. In addition, it
in the VSMC (Fig. 7C), and an immunoblot with anti- has been reported that NO per se induces apoptosis in
Tyr(P) showed that p85 was not tyrosine phosphorylated VSMCs [14–16]. Consistent with these previous studies,
(Fig. 7D). our present study demonstrates that IL-1b induced
VSMC apoptosis in a dose- and time-dependent manner.
Effect of rHuEPO on phosphorylation of Akt
Since this agent could not induce the apoptosis in the
We further explored the effect of rHuEPO on phos- presence of L-NMMA or L-NAME, a specific inhibitor
phorylation of Akt, a potent downstream effector of PI3- of NO synthesis, it was considered that IL-1b induced
kinase. Figure 8A shows the time course of rHuEPO- VSMC apoptosis via the induction of NO. In addition,
induced phosphorylation of Akt. It was rapid with the we also observed that NO donor SNP induced VSMC
maximal effect being achieved after a 3-minute stimula- apoptosis in a dose- and time-dependent manner. More-
tion with rHuEPO and remained enhanced for up to 30 over, we have demonstrated that rHuEPO inhibited the
minutes. Also, rHuEPO induced Akt phosphorylation IL-1b–induced NO production in VSMCs [30, 33]. Also,
in a dose-dependent manner after stimulation with the PKC-dependent pathway is suggested to be involved
rHuEPO for five minutes (Fig. 8B). In addition, phos- in the inhibitory effect of rHuEPO on IL-1b–induced
phorylation of Akt induced by rHuEPO (250 U/mL) was
NO production [30]. Taken together with these results,
apparently diminished in the presence of a specific PI3-
our present study suggests that rHuEPO inhibits IL-1b–kinase inhibitor wortmannin (0.1 mmol/L).
induced apoptosis by at least two mechanisms: rHuEPO
inhibited IL-1b–induced apoptosis as a result of inhibi-Effect of PI3-kinase inhibitor on the anti-apoptotic
tion of IL-1b–stimulated NO production through a PKC-effect of rHuEPO
dependent pathway, and rHuEPO directly inhibited NO-Next, we explored the role of the PI3-kinase–depen-
induced VSMC apoptosis.dent pathway on the anti-apoptotic effect to IL-1b– or
Previously, we and another group reported that EpoRSNP-induced VSMC apoptosis. As shown in Figure 9,
is mRNA expressed in the VSMC [29, 30]. In addition,the anti-apoptotic effects of rHuEPO were significantly
several studies have demonstrated that rHuEPO hasdiminished in the presence of a specific PI3-kinase inhibi-
both a direct vasoconstrictor effect on isolated renal andtor wortmannin (0.1 mmol/L).
mesenteric resistance vessels [31] and a mitogenic effectIn addition, we analyzed the effects on VSMC apopto-
in VSMCs [32]. Also, Carlini et al demonstrated thatsis of wortmannin (0.1 mmol/L) alone. This agent could
rHuEPO stimulates angiogenesis [40]. These findingsnot induce significant VSMC apoptosis. Percentages of
apoptotic cells after 48-hour treatment were as follows: might be explained by a reference to the expression of
b
Fig. 6. Cellular protein tyrosine phosphorylation including EpoR and JAK 2 induced by rHuEPO in VSMCs. Cells were exposed to rHuEPO in
several conditions as described in this article. (A) Time course of cellular protein tyrosine phosphorylation. Cells were exposed to rHuEPO (250
U/mL) for the indicated periods. (B) Dose-dependent effect of cellular protein tyrosine phosphorylation induced by increased concentrations of
rHuEPO. Cells were exposed to graded concentrations of rHuEPO for five minutes. Total cell lysates were blotted with horseradish peroxidase
conjugated anti-Tyr(P) monoclonal antibody PY20 (A and B). (C) Tyrosine phosphorylation of EpoR. After cells were exposed to rHuEPO (250
U/mL) for five minutes, total cell lysates were subjected to immunoprecipitation with either anti-EpoR (aEpoR), or anti-Tyr(P) monoclonal
antibody 4G10 [aTry(P)4G10]. Immunoprecipitates were resolved by 10% SDS-PAGE and immunoblotted with either anti-EpoR (aEpoR) or
anti-Tyr(P) monoclonal antibody PY20 [aTry(P)PY20]. (D) Tyrosine phosphorylation of JAK 2. After cells were exposed to rHuEPO (250 U/mL)
for five minutes, total cell lysates were subjected to immunoprecipitation with either anti-JAK 2 (aJAK 2), anti-JAK 1 (aJAK 1), or anti-Tyr(P)
monoclonal antibody 4G10 [aTyr(P)4G10]. Immunoprecipitates were resolved by 10% SDS-PAGE and immunoblotted with either anti-JAK 2
(aJAK 2), anti-JAK 1 (aJAK 1), or anti-Tyr(P) monoclonal antibody PY20 [aTyr(P)PY20]. The figure shown represents one of three independent
experiments.
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Fig. 7. Association of the p85 subunit of PI3-
kinase with tyrosine-phosphorylated protein
including EpoR in VSMCs. After VSMCs were
deprived of fetal bovine serum for 24 hours,
cells were exposed to rHuEPO (250 U/mL)
for the indicated periods before solubilization.
Equivalent amounts of cell lysate were immu-
noprecipitated with either anti-Tyr(P) antibody
4G10 (aTry(P)4G10), anti-EpoR antibody
(aEpoR), or anti-p85 antibody (ap85) as indi-
cated above the panels. Immunoprecipitates
were resolved by 10% SDS-PAGE and immu-
noblotted with anti-EpoR antibody (aEpoR;
A), anti-p85 antibody (ap85; B and C) or anti-
Tyr(P) antibody PY20 [aTyr(P)PY20; D], as
indicated on the left side of the panel. (D)
The protein samples that included phospho-
tyrosine protein induced by rHuEPO (250
U/mL) for five minutes were used as a positive
control. The figure shown represents one of
three independent experiments.
EpoR in VSMCs. In the present study, we demonstrated phosphorylation of phopholipase C-g1 (PLC-g1) and the
activation of PKC in VSMCs [30].that the EpoR protein was constitutively expressed in
the VSMC by Western blotting analysis. Furthermore, In the present study, we demonstrated that the coun-
tervailing effects of rHuEPO on IL-1b– or SNP–inducedthe present results demonstrated that the inhibitory ef-
fects of rHuEPO on IL-1b– or SNP-induced VSMC apo- VSMC apoptosis were diminished in the presence of
the TK inhibitor genistein. Conversely, the former wasptosis were significantly reversed in the presence of anti-
EpoR antibody. These observations could be considered partially diminished, and the latter was not diminished
in the presence of the PKC inhibitor calphostin C. Theseas supporting evidence of the expression of EpoR per
se in VSMCs. Therefore, it is suggested that EPO might results suggest that the TK-dependent pathway is critical
in the inhibition of apoptosis induced by both agents.have a notable biological effect via its own receptor on
VSMCs as well as on erythroid precursor cells. Indeed, Furthermore, the PKC-dependent pathway might be in-
directly involved in the inhibition of apoptosis inducedwe previously reported that rHuEPO-induced tyrosine
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Fig. 8. Time- and dose-dependent effect of
rHuEPO on phosphorylation of Akt. (A)
After VSMCs were deprived of fetal bovine
serum for 24 hours, cells were exposed to
rHuEPO (250 U/mL) for the indicated peri-
ods. Then total cell lysates were immunoblot-
ted with either antiphosphorylated (Ser-473)
Akt antibody (upper) or anti-Akt antibody
(lower). (B) After VSMCs were deprived of
fetal bovine serum for 24 hours, cells were
exposed to rHuEPO (250 U/mL) for five min-
utes in the presence or absence of wortmannin
(0.1 mmol/L). Then total cell lysates were im-
munoblotted with either antiphosphorylated
(Ser-473) Akt antibody (upper) or anti-Akt
antibody (lower). The figure shown represents
one of three independent experiments.
Fig. 9. Effect of PI3-kinase inhibitor on the countervailing effect of rHuEPO on IL-1b or SNP induced apoptosis. (A) Wortmannin (0.1 mmol/L)
was added to the medium with rHuEPO (250 U/mL) for 48 hours in the presence of 10 ng/mL IL-1b. (B) Wortmannin (0.1 nmol/L) was added
to the medium with rHuEPO (250 U/mL) for 24 hours in the presence of 1000 mmol/L SNP. Data are means 6 SE of at least four separate
experiments. **P , 0.01.
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by IL-1b, since rHuEPO inhibited the IL-1b–stimulated and the PI3-kinase–dependent pathway appears to be
involved in this effect of rHuEPO.NO production through PKC activation [30].
It has been reported that iNOS is induced by inflam-It has been reported that the first step of EPO-medi-
matory cytokines in several types of tissue, includingated signal transduction is EpoR homodimerization-
VSMCs [1, 7–11]. Also, several studies suggest that NOinduced tyrosine phosphorylation and activation of JAK
induces VSMC apoptosis and regulates the overall cell2, followed by the tyrosine phosphorylation of a number
population on a vessel wall [12, 15]. In this context,of cellular proteins, including its own receptor [19–21].
VSMC apoptosis may serve as an adaptive mechanismAlso, it has been reported that after tyrosine phosphory-
to limit the development of vascular hypertrophy. Con-lation of cellular proteins, including its own receptor, a
versely, it has been reported that VSMCs derived fromnumber of SH2-containing proteins, such as PI3-kinase,
advanced atherosclerotic plaques undergo apoptosisbecome associated with them, and their biological func-
more frequently than those derived from normal vesselstions are activated [19–23]. Consistent with these previ-
[43], and this mechanism could substantially weaken theous findings, in the present study, we provided the evi-
vessel wall and promote the rupture of the plaques, adence that rHuEPO induced tyrosine phosphorylation
major cause of acute atherosclerotic syndrome such asof its own receptor and JAK 2 as well as other cellular
acute myocardial infarction or unstable angina [12–15].proteins and association of PI3-kinase with tyrosine-
The precise role of NO on the atherosclerotic VSMCphosphorylated protein, including EpoR in VSMCs. Fur-
apoptosis remains to be elucidated; however, Wang etthermore, our present results demonstrated that the 66
al recently reported about the potential role of NO,kD form of EpoR was constitutively expressed, and the
which is derived from iNOS, on the stabilization and72 kD form of tyrosine-phosphorylated form of EpoR
even regression of atherosclerotic plaque by promotingincreased after stimulation with rHuEPO in VSMCs.
apoptosis of macrophages in the lesion [44]. Therefore,These findings are also consistent with the previous find-
our present results suggest that rHuEPO might play anings that the constitutive EpoR is mainly synthesized as
important role in determining the cellular population ofa 66 kD form and tyrosine phosphorylated form of EpoR
vessel walls even in the atherosclerotic plaques as wellshift in gel mobility from 66 kD to 72 kD in hematopoi-
as modulating the structure of the vasculature.etic cell lines [22, 41].
Recombinant human EPO is now widely used to treatYao and Cooper previously reported that PI3-kinase
anemia in end-stage renal failure. Research has shownmight be able to deliver a survival signal [42]. Also, it
that atherosclerosis is accelerated in patients with end-has been reported that PI3-kinase suppresses apoptotic
stage renal failure [45, 46]. Since hemodialysis patientscell death induced by several stimulations through its
have high levels of cytokines in their blood, NO produc-
downstream effector PKB/Akt [24–26]. Although the
tion is usually stimulated [47–49]. As for the clinical
linkage between the downstream pathway after activa- relevance, it is possible that the inhibitory effect of NO
tion of Akt and its anti-apoptotic effect remains to be production may be related to the acceleration of vascular
elucidated, its phosphorylation appears to be critical hypertrophy and atherosclerosis, or remodeling follow-
for kinase activity [26]. Our study demonstrates that ing the exacerbation of hypertension, which have always
rHuEPO induced phosphorylation of Akt in VSMCs. been problematic for chronic hemodialysis patients un-
In addition, the phosphorylation of Akt induced by der rHuEPO treatment. Clinical studies, however, are
rHuEPO was diminished in the presence of PI3-kinase needed to determine whether rHuEPO may inhibit NO
inhibitor wortmannin. Therefore, it is suggested that production and induce the development of atherosclero-
rHuEPO can activate PI3-kinase and induce Akt phos- sis or hypertension in these patients.
phorylation, namely Akt activation, through a PI3-kinase– In conclusion, our present study demonstrates that
dependent pathway in VSMCs. Importantly, the anti- rHuEPO inhibites IL-1b– or SNP–induced VSMC apo-
apoptotic effects of rHuEPO on IL-1b– or SNP–induced ptosis via its own receptor. The TK-dependent pathway
VSMC apoptosis were diminished in the presence of is essential for these effects of rHuEPO. Also, the PKC-
wortmannin. Consistent with our findings, Bao et al re- dependent pathway might be involved in the countervail-
ported that EPO could induce the activation of PI3- ing effect of rHuEPO on IL-1b–induced apoptosis as a
kinase/Akt signal transduction pathway, which may be result of inhibition of IL-1b–stimulated NO production
necessary to promote the viability of hematopoietic cell through PKC activation. Furthermore, the PI3-kinase–
line [27]. Since we did not demonstrate certain evi- dependent pathway is critical to these countervailing ef-
dence that Akt per se has a critical role in the suppres- fects of rHuEPO on IL-1b– and SNP–induced VSMC
sion of the apoptosis induced by IL-1b or SNP, the apoptosis. Our present results suggest that rHuEPO may
precise role of its phosphorylation remains to be elucid- play an important role in determining the cellular popu-
ated. However, our present findings demonstrate that lation of vessel walls and modulating the structure of the
vasculature.rHuEPO eliminates the anti-apoptotic effects in VSMCs,
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